Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health - KFDA - NewsChannel 10 / Amarillo News, Weather, Sports

Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Analysts Review

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, August 8, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Tenet Healthcare Corp. (NYSE: THC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5592-100free.

Gilead Sciences, Inc. Research Reports

On July 25, 2014, Gilead Sciences, Inc. (Gilead) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the Company's Marketing Authorization Application (MAA) for Zydelig® (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin lymphoma (iNHL). Gilead informed that CHMP's recommendations will now be reviewed by European Commission, the authority that approves medicines for use in 28 countries of the European Union (EU). The Company stated that the CHMP's positive opinion is based on data from two clinical trials - Study 116 and Study 101-09. The full research reports on Gilead are available to download free of charge at:

http://www.analystsreview.com/Aug-08-2014/GILD/report.pdf

Pfizer Inc. Research Reports

On July 30, 2014, Pfizer Inc. (Pfizer) announced that the Company has entered into a definitive agreement to acquire Baxter International Inc.'s (Baxter) portfolio of marketed vaccines for $635 million. In addition, the Company will also acquire a part of Baxter's facility in Orth, Austria, where these vaccines are manufactured. Pfizer informed that Baxter's marketed vaccines portfolio consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C vaccine is used as a protection against meningitis caused by group C meningococcal meningitis (MenC), while FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis (TBE), an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus. Silbermann, Pfizer Vaccines President, said, "Through this acquisition, we will add two high-quality and life-saving vaccines that bring scale and depth to our portfolio." The Company plans to close the transaction by the end of 2014, subject to customary closing conditions as well as regulatory approvals. The full research reports on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Aug-08-2014/PFE/report.pdf

AbbVie Inc. Research Reports

On August 4, 2014, AbbVie Inc. (AbbVie) announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to the Company's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiforme. Glioblastoma multiforme is the most common and most aggressive type of malignant primary brain tumor. Gary Gordon, M.D., Vice President, Oncology Clinical Development, AbbVie, said, "The orphan drug designation is an important regulatory advancement as we further our development in recurrent glioblastoma multiforme, a disease that is uniformly fatal with limited treatment options." The full research reports on AbbVie are available to download free of charge at:

http://www.analystsreview.com/Aug-08-2014/ABBV/report.pdf

Express Scripts Holding Company Research Reports

On August 5, 2014, Express Scripts Holding Company (Express Scripts) released the results of a new analysis highlighting that the U.S. health plan sponsors are expected to spend $9.07 billion on specialty medication services in 2015 that provide no additional value. According to the results, this wasteful expenditure can be avoided if payers applied cost-saving techniques from the pharmacy benefit on medications that are administered through the medical benefit. Further, approx. 50% of Specialty medications that treat complex, chronic conditions, are currently billed through the medical benefit, which lacks the visibility and cost control tools of the pharmacy benefit. The results concluded that inefficient U.S. spending on specialty medications in the medical benefit resulted in a waste of $4.87 billion in 2011. In addition, the results indicated that plans that implement Medical Benefit Management services have resulted in 10-15% savings in specialty spending. The full research reports on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/Aug-08-2014/ESRX/report.pdf

Tenet Healthcare Corp. Research Reports

On August 4, 2014, Tenet Healthcare Corp. (Tenet Health) released its Q2 2014 and H1 2014 financial results. The Company reported Q2 2014 net operating revenues of $4.04 billion, up 66.9% YoY. Thomson Reuters polled 17 analysts that expected the Company to post Q2 2014 EPS of $0.01 on revenues of $3.94 billion. The Company's Q2 2014 net loss attributable to Tenet Health common shareholders came in at $26 million or $0.27 dilute loss per share, compared to net loss of $50 million or $0.49 diluted loss per share in Q2 2013. The Company reported H1 2014 net operating revenues of $7.97 billion, up 65.7% YoY. Net loss attributable to Tenet Health common shareholders was $58 million in H1 2014, compared to $138 million in H1 2013. For Q3 2014, the Company expects earnings per share in the range of a loss of $0.30 per share to income of $0.21 per share. The full research reports on Tenet Health are available to download free of charge at:

http://www.analystsreview.com/Aug-08-2014/THC/report.pdf

About Analysts Review

We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

©2012 PR Newswire. All Rights Reserved.